Literature DB >> 21865142

Prognosis of patients with thyroid cancer who do not undergo surgical treatment: a SEER database analysis.

Alvaro Sanabria1, Luis C Domínguez, Valentín Vega, Camilo Osorio.   

Abstract

BACKGROUND: The treatment for thyroid cancer is surgical. However, some patients do not undergo operations because of comorbidities or other reasons. There is little information about the prognosis of these patients. The aim of the present study was to describe patients with well differentiated thyroid carcinoma who did not undergo surgical treatment and to identify differences in prognostic variables and survival compared with patients treated surgically.
METHODS: We conducted a retrospective review of a prospective cohort collected by the National Cancer Institute obtained from the Surveillance, Epidemiology and End Results (SEER) Program. All patient files with a diagnosis of thyroid cancer were selected (38,493 cases). Finally, 12,416 cases were used for the analysis. Treatment was divided into surgical or nonsurgical groups. Five-year survival rates were estimated and classified by the SEER stage.
RESULTS: Eighty-six patients did not receive surgical treatment. These patients were older, had more advanced tumours and their treatment was less associated with complementary radiotherapy. Five-year overall survival rates were 96.7% for surgical patients vs. 56.8% for nonsurgical patients (p<0.001). The overall survival in the nonsurgery group for localised tumours decreased 14.9%, for regional tumours decreased 49.9% and for distant tumours decreased 61.8%. DISCUSSION: The patients who did not undergo surgical treatment showed less than 5-year overall survival. The SEER database does not offer information about comorbidities that could explain these differences.

Entities:  

Mesh:

Year:  2011        PMID: 21865142     DOI: 10.1007/s12094-011-0716-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  21 in total

1.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

2.  The place of non-surgical methods in diagnosis and management, and the long-term value of treatment of thyroid cancer.

Authors:  K E Halnan
Journal:  Br J Surg       Date:  1965-10       Impact factor: 6.939

3.  An observational trial for papillary thyroid microcarcinoma in Japanese patients.

Authors:  Yasuhiro Ito; Akira Miyauchi; Hiroyuki Inoue; Mitsuhiro Fukushima; Minoru Kihara; Takuya Higashiyama; Chisato Tomoda; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

4.  Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Authors:  Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

Review 5.  Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment.

Authors:  Harold P Freeman; Kenneth C Chu
Journal:  Surg Oncol Clin N Am       Date:  2005-10       Impact factor: 3.495

Review 6.  Improvement of informed consent and the quality of consent documents.

Authors:  Michael Jefford; Rosemary Moore
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

7.  Non-surgical treatment of thyroid carcinoma.

Authors:  V K Sethi
Journal:  Ann Acad Med Singapore       Date:  1981-07       Impact factor: 2.473

8.  AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States.

Authors:  Philip I Haigh; David R Urbach; Lorne E Rotstein
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

9.  Risk factor analysis in differentiated thyroid cancer.

Authors:  B Cady; C E Sedgwick; W A Meissner; M S Wool; F A Salzman; J Werber
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

Review 10.  The treatment of metastatic thyroid disease.

Authors:  K Y Lee; J M Loré
Journal:  Otolaryngol Clin North Am       Date:  1990-06       Impact factor: 3.346

View more
  5 in total

1.  Candidate agents for papillary thyroid cancer identified by gene expression analysis.

Authors:  Wei Zhu; Chen Li; Zhilong Ai
Journal:  Pathol Oncol Res       Date:  2013-03-22       Impact factor: 3.201

2.  Should small papillary thyroid cancer be observed? A population-based study.

Authors:  Naris Nilubol; Electron Kebebew
Journal:  Cancer       Date:  2014-11-25       Impact factor: 6.860

3.  1.5-2 cm tumor size was not associated with distant metastasis and mortality in small thyroid cancer: A population-based study.

Authors:  Kyunghwa Han; Eun-Kyung Kim; Jin Young Kwak
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

4.  Long Noncoding RNA H19 Inhibits Cell Viability, Migration, and Invasion Via Downregulation of IRS-1 in Thyroid Cancer Cells.

Authors:  Peng Wang; Guoqing Liu; Weimin Xu; Haixia Liu; Qingao Bu; Diwen Sun
Journal:  Technol Cancer Res Treat       Date:  2017-10-03

5.  Population-based study evaluating and predicting the probability of death resulting from thyroid cancer among patients with papillary thyroid microcarcinoma.

Authors:  Kun Wang; Jing Xu; Shuyu Li; Shiyang Liu; Lin Zhang
Journal:  Cancer Med       Date:  2019-10-06       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.